Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Abilify, Lixiana and Others under PMDA Risk Review
December 12, 2017
- MHLW Proposes Physician Fee for Proper Antibiotic Use in Children, Aims to Cut Unnecessary Use: Chuikyo
December 11, 2017
- First Generics for 8 APIs, AGs of Avapro, Talion Receive Listing on Dec. 8
December 8, 2017
- Govt’s Modified PMP Plan: “1-Year Cutoff” Extended for 3 Years, 25% of Firms Could Now Maintain Full Prices
December 8, 2017
- Easing of Proposed PMP Requirements Likely, Major Focus on “One-Year Cutoff” and “Category I” Scope
December 7, 2017
- (Update) NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018
December 6, 2017
- ICH Completes Guidelines for Multiregional Clinical Trials; Could Accelerate Simultaneous Global Development
December 6, 2017
- MHLW Reviewing PMP in View of People’s Understanding: Health Insurance Chief
December 6, 2017
- Checklist Presented for Excluding Foundation-Funded Programs from “Specified Clinical Research”
December 6, 2017
- NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018
December 6, 2017
- MHLW Advisory Panel Backs Otsuka’s Schizophrenia Med Brexpiprazole and More
December 5, 2017
- Novo’s Semaglutide Stumbles as Panel Puts a Hold on Japan Approval
December 5, 2017
- Opdivo Earns Orphan Status for Malignant Pleural Mesothelioma
December 4, 2017
- MHLW Floats Incentives to Stem Antibiotic Overuse, but Payer Reps Negative: Chuikyo
December 4, 2017
- MHLW Presents Example of COI Management Guidelines for “Specified Clinical Research”
December 4, 2017
- CEFP Members Want Quicker Cuts for Off-Patent Drugs, Pricing Debate Enters Final Stretch
December 4, 2017
- Keytruda Earns Lymphoma Nod, Novo’s Norditropin Label Expanded
December 1, 2017
- LDP Lawmakers Lash Out at Govt's Drug Pricing Proposals
December 1, 2017
- Full-Scale CEA Rollout to Be Delayed into FY2019: Official
December 1, 2017
- MHLW Looks to Lift Ban on Exports of Plasma Fraction Products by FY2020
December 1, 2017
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…